Comparing One Daily vs Two Daily Intakes of Artesunate and Amodiaquine for Malaria Treatment
Author Information
Author(s): Ndiaye Jean Louis A, Faye Babacar, Diouf Amadou M, Kuété Thomas, Cisse Moustapha, Seck Papa A, Brasseur Phillipe, Same-Ekobo Albert, Lameyre Valerie, Gaye Oumar
Primary Institution: Department of Parasitology, Faculty of Medicine, Cheikh Anta Diop University, Dakar, Senegal
Hypothesis
Is the efficacy and safety of artesunate plus amodiaquine as a single daily intake non-inferior to two daily intakes in treating uncomplicated falciparum malaria?
Conclusion
The study confirms that artesunate plus amodiaquine is effective and well-tolerated whether administered as one or two daily intakes.
Supporting Evidence
- The adequate responses to treatment were similar for both treatment regimens on D14.
- The drug was well tolerated with similar safety profiles in both groups.
- Gastrointestinal disorders and pruritus were the main adverse events reported.
Takeaway
This study shows that taking malaria medicine once a day is just as good as taking it twice a day, which might make it easier for people to take their medicine.
Methodology
A randomized, comparative, open-label study with a three-day treatment and 14-day follow-up, involving patients with confirmed malaria.
Potential Biases
Potential bias due to the open-label design and lack of placebo control.
Limitations
The study only followed patients for 14 days, which may not capture long-term efficacy and safety.
Participant Demographics
Patients included were adults and children weighing more than 10 kg with uncomplicated malaria.
Statistical Information
P-Value
0.0389
Confidence Interval
(-3.00; 1.11]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website